Product Description
Carboplatin interferes with the development of the genetic material in a cell, the DNA. This stops it from dividing into 2 new cells and kills it. Carboplatin is a chemotherapy treatment for many different types of cancer. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/carboplatin)
Mechanisms of Action: DNA Synthesis Inhibitor, Mitosis Inhibitor, Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location:
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belarus, Belgium, Bosnia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Kazakhstan, Korea, Latvia, Malaysia, Mexico, Moldova, Montenegro, Morocco, Netherlands, New Zealand, Norway, Panama, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 223
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Adenocarcinoma|Anal Cancer|Bladder Cancer|Breast Cancer|Carcinosarcoma|Cervical Cancer|Clear Cell Adenocarcinoma|Clear Cell Sarcoma|Diffuse Large B-Cell Lymphoma|Endometrial Cancer|Endometrioid Carcinoma|Esophageal Cancer|Fallopian Tube Cancer|Gastrointestinal Cancer|Glioblastoma|Head and Neck Cancer|Hodgkin Lymphoma|Inflammatory Breast Cancer|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Mesothelioma|Mixed Tumor, Mullerian|Nasopharyngeal Cancer|Non-Small-Cell Lung Cancer|Nose Cancer|Other|Ovarian Cancer|Pain Unspecified|Peritoneal Cancer|Prostate Cancer|Retinoblastoma|Serous Cystadenocarcinoma|Small Cell Lung Cancer|Squamous Cell Carcinoma|Tobacco Use Disorder|Transitional Cell Carcinoma|Triple Negative Breast Cancer|Unilateral Breast Cancer|Uterine Cancer
Phase 2: Adenoid Cystic Carcinoma|Anus Cancer|Brain Cancer|Carcinoma, Adenosquamous|Colorectal Cancer|Edema|Erythema|Gliosarcoma|Laryngeal Cancer|Lip Cancer|Lung Cancer|Male Breast Cancer|Mouth Cancer|Neoplastic Cells, Circulating|Neuroendocrine Carcinoma|Oncology Solid Tumor Unspecified|Oncology Unspecified|Oropharyngeal Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma|Penile Cancer|Penile Diseases|Salivary Gland Cancer|Sarcoma|Thymoma|Urogenital Cancer|Urologic Cancer
Phase 1: Epilepsy|Kidney Cancer|Kidney Diseases|Melanoma|Muscle Spasticity
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03997370 |
NRG-GY022 | P1 |
Recruiting |
Kidney Cancer|Kidney Diseases |
2027-02-06 |
2023-11-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT05733689 |
RANT-GC Trial | P1 |
Recruiting |
Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer |
2026-02-01 |
50% |
2025-07-09 |
|
NCT06953323 |
WJB001-002-I | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2029-06-30 |
12% |
2025-08-14 |
Primary Endpoints|Start Date |
NCT07020221 |
VS-7375-101 | P2 |
Recruiting |
Colorectal Cancer|Gastrointestinal Cancer|Pancreatic Cancer|Adenocarcinoma|Pancreatic Ductal Carcinoma|Non-Small-Cell Lung Cancer |
2028-12-01 |
12% |
2026-01-24 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06822543 |
TROPICAL-1 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer|Brain Cancer |
2028-06-30 |
2% |
2025-09-30 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT06630325 |
STUDY00026643 | P2 |
Active, not recruiting |
Sarcoma|Pancreatic Cancer|Breast Cancer|Ovarian Cancer|Prostate Cancer |
2027-12-31 |
12% |
2026-01-08 |
|
NCT02876107 |
NCI-2017-00619 | P2 |
Active, not recruiting |
Erythema|Breast Cancer|Edema |
2027-10-31 |
12% |
2025-10-11 |
|
NCT05118854 |
NCI-2021-10907 | P2 |
Recruiting |
Lung Cancer |
2027-10-20 |
12% |
2025-10-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06351332 |
ZAP-IT | P2 |
Active, not recruiting |
Male Breast Cancer|Triple Negative Breast Cancer |
2027-03-01 |
12% |
2026-01-13 |
Primary Endpoints|Treatments|Trial Status |
NCT06353906 |
PRIAM | P2 |
Recruiting |
Penile Cancer|Squamous Cell Carcinoma|Urologic Cancer|Urogenital Cancer|Penile Diseases |
2026-10-14 |
12% |
2024-08-17 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT04159142 |
CSPC-KAL-BC-16 | P2 |
Recruiting |
Triple Negative Breast Cancer |
2026-06-20 |
2% |
2025-09-12 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT04709276 |
CHAMP | P2 |
Active, not recruiting |
Prostate Cancer|Neuroendocrine Carcinoma |
2026-02-01 |
2% |
2025-09-12 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05832827 |
Artemis | P2 |
Recruiting |
Thymoma |
2025-12-31 |
12% |
2023-10-24 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT04681417 |
RETINO2018 | P3 |
Recruiting |
Retinoblastoma |
2035-01-20 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT05991388 |
Glo-BNHL | P3 |
Recruiting |
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell |
2031-05-01 |
13% |
2024-11-27 |
Primary Endpoints|Treatments |
2018-003335-29 |
2018-003335-29 | P3 |
Active, not recruiting |
Other |
2029-10-15 |
2022-03-13 |
Treatments |
|
2024-520050-38-00 |
20240178 | P3 |
Not yet recruiting |
Small Cell Lung Cancer|Nose Cancer|Tobacco Use Disorder |
2029-07-15 |
|||
NCT07168200 |
SHR-1316-305 | P3 |
Recruiting |
Cervical Cancer |
2028-04-01 |
46% |
2025-11-18 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT05256225 |
NCI-2022-01540 | P3 |
Recruiting |
Clear Cell Adenocarcinoma|Endometrioid Carcinoma|Endometrial Cancer|Carcinosarcoma|Clear Cell Sarcoma |
2027-10-31 |
2026-02-05 |
Primary Endpoints|Treatments |
|
2022-502889-24-00 |
kp-acs-2 | P3 |
Recruiting |
Pain Unspecified |
2027-08-31 |
2025-05-02 |
Treatments |
|
NCT04095364 |
NRG-GY019 | P3 |
Active, not recruiting |
Serous Cystadenocarcinoma|Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer |
2027-02-01 |
2025-05-21 |
Primary Endpoints|Treatments|Trial Status |
|
NCT04574960 |
NAUTICAL | P3 |
Recruiting |
Transitional Cell Carcinoma|Bladder Cancer |
2026-12-01 |
2025-07-22 |
Primary Endpoints |
|
NCT04585490 |
IRB-54807 | P3 |
Recruiting |
Non-Small-Cell Lung Cancer |
2026-04-01 |
45% |
2024-04-18 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT05468489 |
ASTRIDE | P3 |
Active, not recruiting |
Small Cell Lung Cancer |
2026-02-28 |
40% |
2025-10-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT04974398 |
AK105-304 | P3 |
Active, not recruiting |
Nasopharyngeal Cancer |
2026-02-23 |
66% |
2025-04-15 |
Primary Endpoints|Treatments |